3GONZALEZ FJ,GELBOIN HV.Role of human cytochromes P450 in the ietabolic activation of chemical cavcinogens and toxins[J].Drug Metab Rev,1994,26(1-2):165.
5ONG H T.The statin studies:from targetinghypercholesterolaemia to targeting thehigh-risk patient[J].QJM,2005,98(8):599-614.
6JACOBSON T A.Statin safety:lessons from new drug applications for marketed statins[J].Am J Cardiol,2006,97(8A):44C-51C.
7UMEJI K,UMEMOTO S,ITOH S,et al.Comparative effects of pitavastatin and probucol on oxidative stress,Cu/Zn superoxide dismutase,PPAR-gamma,and aortic stiffness inhypercholesterolemia[J].Am J Physiol Heart Circ Physiol,2006,291(5):H2522-2532.
8KINLAY S.Potential vascular benefits of statins[J].Am J Med,2005,118(Suppl 12A):62-67.
9SJOHOLM A,BERGGREN PO,COONEY R V.gamma-tocopherol partially protects insulin-secreting cells against functional inhibition by nitric oxide[J].Biochem Biophys Res Commun,2000,277 (2):334-340.
10WAGNER A H,SCHWABE O,HECKER M.Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ[J].Br J Pharmacol,2002,136(1):143-149.
